Ludwig Cancer Research is an international community of distinguished scientists dedicated to preventing and controlling cancer. American businessman Daniel K. Ludwig began to support cancer research with the establishment of the Ludwig Institute for Cancer Research in 1971. Today, the scientific efforts endowed through his resources have grown to encompass the Ludwig Institute and the Ludwig Centers and professorships at six U.S. institutions.

Leadership

Board of Directors

A Board of Directors has the ultimate responsibility for the Ludwig Institute for Cancer Research and the Ludwig Fund. Although they are separate Boards, the members are the same. Several board members also served as trustees of the Virginia and D.K. Ludwig Fund for Cancer Research, which oversaw the endowment of the six Ludwig Centers in the United States.

John L. Notter
Chair of the Board; Board Member, Conrad N. Hilton Foundation
Nancy E. Davidson, MD
Fred Hutchinson Cancer Research Center
Olivier Dunant
Law firm of Borel & Barbey
John D. Gordan III
Law firm of Morgan, Lewis & Bockius (retired)
Alexandra Johnson
Law firm of Bär & Karrer
Barbara S. Jones
Law firm of Bracewell LLP
Philip A. Pizzo, MD
Stanford University School of Medicine
Edward A. McDermott Jr.
President and Chief Executive Officer
Chi Van Dang, MD, PhD
Scientific Director
Scientific Advisory Committee

The Scientific Advisory Committee is a group of distinguished independent scientists and clinicians appointed by the Scientific Director of the Ludwig Institute to advise on emerging areas of cancer research and development that might help the Institute fulfill its mission. The group also assists in the scholarly review of Institute scientists.

History

Daniel K. Ludwig was born June 24, 1897, in South Haven, Michigan, USA. By the 1960s he was among the richest men in the world, with a self-made empire of some 200 companies. By the time of his death, he had pioneered the modern supertanker, participated in major oil and gas projects throughout the world, become a major investor and operator in the production of coal and other minerals, acquired and developed luxury hotels and other real estates, and developed a forest-products and agricultural enterprise that encompassed three million acres in the Amazon basin.

In 1971, he launched the Ludwig Institute for Cancer Research (he had to be persuaded strongly to allow his name to be used), endowing it with nearly all of his international holdings. That endowment is managed by the LICR Fund.

Upon his death in August 1992, Mr. Ludwig’s estate also provided for cancer research support at six leading U.S. academic institutions.

READ DANIEL LUDWIG’S FOUNDING STATEMENT

How we’re organized

The Ludwig Institute for Cancer Research Ltd is an international not-for-profit organization with a legacy of pioneering cancer discoveries that spans more than 45 years. The Institute provides its scientists with the resources and the flexibility to realize the life-changing potential of their work and see their discoveries advance human health. This philosophy, combined with robust translational programs, maximizes the potential of breakthrough discoveries to be more attractive for commercial development.

The Ludwig Institute conducts its own research and clinical trials, bridging the most basic questions of life to the most pressing needs of cancer care. Since its inception, the Institute has invested more than $1.8 billion of its own resources in cancer research, and has an endowment valued at $1.5 billion.

In addition, Ludwig Centers and Ludwig professorships have been established at six leading U.S. institutions. The Centers, created in 2006, operate independently of the Ludwig Institute but work collaboratively with each other and with the Institute at the forefront of cancer research. Each Center has a secure level of funding that generates more than $2 million a year in perpetuity. This funding empowers the Centers to attract the best and brightest scientists and provides unconstrained resources to tackle the most challenging projects for the benefit of cancer patients.

Funding

The LICR Fund

The LICR Fund Inc. is a US 501(c)3 organization that manages the assets of the Ludwig Institute for Cancer Research.

The LICR Fund’s investment goal is to provide sustainable core spending for the Ludwig Institute while maintaining the purchasing power of the Fund for future generations of scientists. The Fund, valued currently at $1.5 billion, is overseen by a Board of Directors, which determines investment policy and objectives, defines guidelines for the allocation of assets and—together with the Institute’s Investment Office—appoints and evaluates outside investment managers.

The Fund’s orientation is global and broadly diversified, with an investment portfolio incorporating a range of asset classes and strategies designed to achieve its risk-adjusted objectives.

The Virginia and D.K. Ludwig Fund

The Virginia and D.K. Ludwig Fund for Cancer Research endowed the Ludwig Centers under the terms of the will of Daniel Ludwig. Each Center is endowed, providing generous and secure funding for the indefinite future.

Careers

Ludwig is always hungry for creative scientific minds and brilliant people to help further our mission. Check this space regularly for the latest job openings at our locations around the world.

Postdoctoral Research Scientist in RNA Modification and Epigenetics
Oxford

Grade 7: Salary in range £32,817 – £40,322 per annum

The Ludwig Institute for Cancer Research is looking for a Postdoctoral Research Scientist in RNA Modification and Epigenetics to join Professor Yang Shi’s research group to investigate newly identified RNA m6A methyltransferases. This is an exciting opportunity to join the world-leading institute.

As Postdoctoral Research Scientist in RNA Modification and Epigenetics, you will analyze newly identified RNA m6A methyltransferases using biochemical, molecular and genetic approaches to investigate their functions and mechanisms of action in both cell lines and model organisms. You will contribute directly to scientific discussions with members of the group and collaborators to develop the project and future research. You will assist in the dissemination of findings through writing manuscripts and work towards publishing your results in international journals. You will also use your expertise to supervise and train junior staff in chromatin and cancer biology.

You will have a Ph.D. degree in a relevant field and previous laboratory experience relevant to the project, as well as a significant background in RNA biochemistry. It is essential that you have a strong publication record for your career stage, such as first-author publications in internationally recognised journals and a good attention to detail. You will also have excellent written and verbal communication skills.

This post is fixed term for 3 years and is funded by the Ludwig Institute for Cancer Research.

Applications must be made online by 12.00 noon (UK time) on 8th March 2021.

 

Go To Oxford Page    

See Full Job Posting    

Postdoctoral Researcher in Mutagenesis
Oxford

Grade 7: Salary in range £32,817 – £40,322 per annum

We are seeking a highly motivated Postdoctoral Researcher in Mutagenesis to join Francesco Boccellato’s and Benjamin Schuster-Böckler’s research groups at the Ludwig Institute for Cancer Research, Oxford Branch, to drive the development of ex-vivo models of carcinogenesis.

You will develop human organoid systems to test the mutagenic effect of different environmental stresses. Together with our team of experienced bioinformaticians, you will then computationally compare the observed genomic mutation patterns to known signatures, with the aim to reveal their underlying biological cause. This position would be ideal for a wet-lab scientist who would like to work at the cutting edge of molecular cancer research, stem cells and bioinformatics.

It is essential that you have a PhD/ DPhil (or close to completion) in a quantitative science with research experience in academia or industry, previous publishing experience, ideally with a scientific or technical focus, with experience in working in a BSL2 environment in cell culture technologies, nucleic acid and protein extraction and analysis. You will have a proven ability to deliver high-quality novel research, for example through journal publications, patents or other IP and a good working knowledge and understanding of how to conduct a successful research programme and develop new avenues of research. Close working and collaboration with other scientists will require excellent communication skills, both written and oral, with the ability to present to the scientific community and the lay public.

Applications for this vacancy are to be made online and you will be required to upload a supporting statement and CV as part of your online application. Your supporting statement must explain how you meet each of the selection criteria for the post using examples of your skills and experience.

This post is offered full-time on a fixed term contract until 31 December 2022 and is funded by the Ludwig Institute for Cancer Research.

Applications must be made online by 12.00 noon (UK time) on 8th March 2021.

Go To Oxford Page    

See Full Job Posting    

Vacancy: Postdoctoral Researcher – T Cells
Oxford

Grade 7: £32,817 – £40,322 per annum (with discretionary range to £44,045)

We are seeking a motivated Postdoctoral Researcher in T Cells with a research background in Immunology to join Professor Xin Lu’s laboratory in understanding the molecular mechanisms of tumor suppression.

You will work with the research groups of Professor Lu, Professor McMichael and Associate Professor Gillespie to study T cell response to checkpoint blockade-based therapy in esophageal Cancer patients. You will be responsible for managing your own academic research and administrative activities. You will collaborate in the preparation of scientific reports and journal articles and represent the research group at external meetings/seminars, either with other members of the group or alone.

It is essential that you hold PhD/DPhil (or are close to completion) in a relevant discipline and have experience within immunology and the culture and cloning of T cells. You will have a first author publication in an international peer-reviewed journal and have excellent communication skills.

Applications for this vacancy are to be made online and you will be required to upload a supporting statement and CV as part of your online application. Your supporting statement must explain how you meet each of the selection criteria for the post using examples of your skills and experience.

This post is offered full-time on a fixed term contract for 3 years and is funded by the Department.

Applications must be made online by 12.00 noon (UK time) on Wednesday 21st April 2021

Go To Oxford Page    

See Full Job Posting    

Contact

Baltimore

Ludwig Center at Johns Hopkins
1650 Orleans Street, Cancer Research Building, Room 590
Baltimore, Maryland, U.S. 21287

T 410 955 8878
F 410 955 0548

Boston Harvard

Ludwig Center at Harvard
450 Brookline Avenue
Boston, Massachusetts, U.S. 02215

T 617 632 3985
F 617 632 3408

Boston MIT

Ludwig Center at MIT
77 Massachusetts Avenue, 76-158
Cambridge, Massachusetts, U.S. 02139

T 617 258 5159
F 617 258 5213

Chicago

Ludwig Center at the University of Chicago
5758 South Maryland Avenue MC 9006
Chicago, Illinois, U.S. 60637

T 773 702 0817
F 773 834 7233

Lausanne

Ludwig Institute for Cancer Research, Lausanne
Agora Research Center
Rue du Bugnon 25A, CH-1005 Lausanne

T (41) 21 545 10 77
F (41) 21 692 59 95

New York HQ

Ludwig Institute for Cancer Research
666 Third Avenue, 28th floor
New York, New York, U.S. 10017

T (212) 450 1500
F (212) 450 1565

New York MSK

Ludwig Center at MSK
1275 York Avenue, Box 212
New York, New York, U.S. 10065

T 646 888 3165
F 646 422 0453

Oxford

Ludwig Institute for Cancer Research, Oxford
Nuffield Department of Clinical Medicine
Old Road Campus Research Building
off Roosevelt Drive, Headington, Oxford, OX3 7DQ, UK

T +44 (0) 1865 617507

San Diego

Ludwig Institute for Cancer Research, San Diego
9500 Gilman Drive,
Cellular and Molecular Medicine East Building
La Jolla, California, U.S. 92093-0670

T 858 534 7802
F 858 534 7750

Stanford

Ludwig Center at Stanford
Lokey Stem Cell Research Building
265 Campus Dr., 3rd Floor
Stanford, California, U.S. 94305-5323

T 650 234 0675

Zurich

Ludwig Institute for Cancer Research
Stadelhoferstrasse 22
8001 Zurich, Switzerland

T (41) (0) 44 267 62 62

Baltimore
Boston Harvard
Boston MIT
Chicago
Lausanne
New York HQ
New York MSK
Oxford
San Diego
Stanford
Zurich
Founding statement

In creating this organization I have been guided by certain principles which throughout my life I have found to be highly effective. Success in any complex enterprise consists in bringing the best minds to bear on each problem, in providing the best resources possible, and in putting each concept into practice whenever and wherever the opportunities are most favorable. I believe firmly in the value of applying these principles in grappling with tasks as momentous as finding ways to relieve the human suffering caused by cancer.

Why should this undertaking be international? The rare vision and ability needed in the battle against cancer are not limited by frontiers, and the scientists who possess these gifts must be sought wherever they are to be found. Nor does cancer reveal itself in the same guise in every nation, but strikes different populations in different forms. Yet despite the growing necessity for concerted worldwide effort, I find no agency, which has both the truly international scope and the substantial resources, which I deem essential for a comprehensive attack on human cancer.

In my judgment the ultimate conquest of this frightful disease is not yet in sight, and the same view is held by most informed physicians and scientists in bio-medical research. In contrast to those who would yield to undue optimism, and who hope for too much from present programs. I am persuaded that eventual mastery of cancer will come only from intense and unremitting scientific exploration over many decades. This should not be hindered by the changing policies of governments and the vagaries of public interest. Accordingly it is my intention that the Institute shall be so structured as to ensure secure and continuing support for the attainment of its aims. The elimination of cancer will surely rank as one of man’s greatest and uncontroversial achievements. That day may be long delayed. How long we cannot tell. But I do not doubt that it will surely come.

D.K. Ludwig
December 17, 1974

Notice
?

You are now leaving Ludwig Cancer Research's website and are going to a website that is not operated by the association. We are not responsible for the content or availability of linked sites. Do you wish to continue?

Continue
Cancel